Logo image of ABSI

ABSCI CORP (ABSI) Stock Fundamental Analysis

NASDAQ:ABSI - US00091E1091 - Common Stock

2.425 USD
+0.02 (+1.04%)
Last: 9/5/2025, 2:17:37 PM
Fundamental Rating

3

Overall ABSI gets a fundamental rating of 3 out of 10. We evaluated ABSI against 542 industry peers in the Biotechnology industry. ABSI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ABSI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABSI had negative earnings in the past year.
In the past year ABSI has reported a negative cash flow from operations.
ABSI had negative earnings in each of the past 5 years.
ABSI had a negative operating cash flow in each of the past 5 years.
ABSI Yearly Net Income VS EBIT VS OCF VS FCFABSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ABSI has a Return On Assets (-53.98%) which is in line with its industry peers.
ABSI has a better Return On Equity (-65.35%) than 60.15% of its industry peers.
Industry RankSector Rank
ROA -53.98%
ROE -65.35%
ROIC N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ABSI Yearly ROA, ROE, ROICABSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ABSI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABSI Yearly Profit, Operating, Gross MarginsABSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

ABSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABSI has more shares outstanding
Compared to 5 years ago, ABSI has more shares outstanding
The debt/assets ratio for ABSI has been reduced compared to a year ago.
ABSI Yearly Shares OutstandingABSI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ABSI Yearly Total Debt VS Total AssetsABSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 0.91, we must say that ABSI is in the distress zone and has some risk of bankruptcy.
ABSI has a Altman-Z score of 0.91. This is in the better half of the industry: ABSI outperforms 63.10% of its industry peers.
ABSI has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ABSI has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ABSI outperforms 49.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.91
ROIC/WACCN/A
WACC9.88%
ABSI Yearly LT Debt VS Equity VS FCFABSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ABSI has a Current Ratio of 4.39. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
ABSI has a Current ratio (4.39) which is comparable to the rest of the industry.
ABSI has a Quick Ratio of 4.39. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.39, ABSI perfoms like the industry average, outperforming 50.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.39
ABSI Yearly Current Assets VS Current LiabilitesABSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

ABSI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.64%.
ABSI shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.48%.
ABSI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.09% yearly.
EPS 1Y (TTM)-0.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)27.48%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%-53.31%

3.2 Future

The Earnings Per Share is expected to grow by 12.09% on average over the next years. This is quite good.
The Revenue is expected to grow by 73.48% on average over the next years. This is a very strong growth
EPS Next Y8.09%
EPS Next 2Y13.84%
EPS Next 3Y17.62%
EPS Next 5Y12.09%
Revenue Next Year6.32%
Revenue Next 2Y124.55%
Revenue Next 3Y106.91%
Revenue Next 5Y73.48%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABSI Yearly Revenue VS EstimatesABSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ABSI Yearly EPS VS EstimatesABSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABSI. In the last year negative earnings were reported.
Also next year ABSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABSI Price Earnings VS Forward Price EarningsABSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABSI Per share dataABSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

ABSI's earnings are expected to grow with 17.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.84%
EPS Next 3Y17.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABSI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABSCI CORP

NASDAQ:ABSI (9/5/2025, 2:17:37 PM)

2.425

+0.02 (+1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners59.89%
Inst Owner Change4.84%
Ins Owners6.46%
Ins Owner Change1.73%
Market Cap362.59M
Analysts82.67
Price Target8.29 (241.86%)
Short Float %23.04%
Short Ratio5.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.25%
Min EPS beat(2)-10.99%
Max EPS beat(2)10.49%
EPS beat(4)1
Avg EPS beat(4)-4.09%
Min EPS beat(4)-13.12%
Max EPS beat(4)10.49%
EPS beat(8)1
Avg EPS beat(8)-4.03%
EPS beat(12)2
Avg EPS beat(12)-8.9%
EPS beat(16)2
Avg EPS beat(16)-13.12%
Revenue beat(2)0
Avg Revenue beat(2)-33.39%
Min Revenue beat(2)-54.7%
Max Revenue beat(2)-12.08%
Revenue beat(4)0
Avg Revenue beat(4)-33.74%
Min Revenue beat(4)-63.32%
Max Revenue beat(4)-4.87%
Revenue beat(8)0
Avg Revenue beat(8)-46.41%
Revenue beat(12)2
Avg Revenue beat(12)-35.35%
Revenue beat(16)2
Avg Revenue beat(16)-35.33%
PT rev (1m)-13.8%
PT rev (3m)-10.94%
EPS NQ rev (1m)-8.32%
EPS NQ rev (3m)-23.64%
EPS NY rev (1m)-1.58%
EPS NY rev (3m)2.88%
Revenue NQ rev (1m)-27.49%
Revenue NQ rev (3m)-83.32%
Revenue NY rev (1m)-17.09%
Revenue NY rev (3m)-41.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 87.62
P/FCF N/A
P/OCF N/A
P/B 2.09
P/tB 2.79
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.03
BVpS1.16
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.98%
ROE -65.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.52%
Cap/Sales 7.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.39
Altman-Z 0.91
F-Score4
WACC9.88%
ROIC/WACCN/A
Cap/Depr(3y)44.41%
Cap/Depr(5y)179.67%
Cap/Sales(3y)101.78%
Cap/Sales(5y)229.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y8.09%
EPS Next 2Y13.84%
EPS Next 3Y17.62%
EPS Next 5Y12.09%
Revenue 1Y (TTM)27.48%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%-53.31%
Revenue Next Year6.32%
Revenue Next 2Y124.55%
Revenue Next 3Y106.91%
Revenue Next 5Y73.48%
EBIT growth 1Y-18.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.93%
EBIT Next 3Y7.61%
EBIT Next 5YN/A
FCF growth 1Y7.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.72%
OCF growth 3YN/A
OCF growth 5YN/A